Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra
OIS Podcast | Ophthalmology's leading Podcast
English - May 14, 2019 17:00 - 23 minutes - 10.9 MB - ★★★★★ - 30 ratingsInvesting Business Health & Fitness ophthalmology investment venture capital entrepreneurs oftalmólogo ophthalmic key opinion leader seco ascrs aao Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Avedro CEO Reza Zadno Walks Us Through the Recent IPO, Reimbursement Wins, and Future Potential
Next Episode: Mitro Opens Up About Aerie’s Programs
Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?